ADORA2A and neoplasm: Additionally, co-blockade of the CD39/CD73/A2AR adenosinergic pathway resulted in increased IFN-γ secretion and reduced tumor load in a multiple myeloma model, highlighting the potential therapeutic benefit of targeting multiple points within the adenosinergic pathway [189].